The autonomic nervous system as a therapeutic target in heart failure

• Verfasst von: Bilsen, Marc van [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Titel: The autonomic nervous system as a therapeutic target in heart failure
• Titelzusatz: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
• Verf.angabe: Marc van Bilsen, Hitesh C. Patel, Johann Bauersachs, Michael Böhm, Martin Borggrefe, Dirk Brutsaert, Andrew J. S. Coats, Rudolf A. de Boer, Gilles W. de Keulenaer, Gerasimos S. Filippatos, John Floras, Guido Grassi, Ewa A. Jankowska, Lilian Kornet, Ida G. Lunde, Christoph Maack, Felix Mahfoud, Piero Pollesello, Piotr Ponikowski, Frank Ruschitzka, Hani N. Sabbah, Harold D. Schultz, Petar Seferovic, Riemer H. J. A. Slart, Peter Taggart, Carlo G. Tocchetti, Linda W. Van Laake, Faiez Zannad, Stephane Heymans, and Alexander R. Lyon
• E-Jahr: 2017
• Jahr: 26 September 2017
• Umfang: 18 S.
• Fussnoten: Gesehen am 14.08.2018 ; Online publish-ahead-of-print 26 September 2017
• Titel Quelle: Enthalten in: European journal of heart failure
• Ort Quelle: Oxford : Wiley, 1999
• Jahr Quelle: 2017
• Band/Heft Quelle: 19(2017), 11, Seite 1361-1378
• ISSN Quelle: 1879-0844
• DOI: doi:10.1002/ejhf.921
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Autonomic dysfunction
• Sach-SW: Devices and nerve ablation
• Sach-SW: Heart failure
• Sach-SW: Parasympathetic
• Sach-SW: Sympathetic
• K10plus-PPN: 1580041574

Abstract

Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?